Given the potential role of PKM2 in the pathogenesis of CAD, we hypothesized that plasma PKM2 concentrations would be associated with the clinical severity of CAD and the occurrence of major adverse cardiovascular events (MACEs) in CAD patients. The gene discussed is PKM; the disease is coronary artery disorder.